Related Experiment Video
Updated: May 1, 2026
09:57
System for Efficacy and Cytotoxicity Screening of Inhibitors Targeting Intracellular Mycobacterium tuberculosis
Published on: April 5, 2017
8.1K
Summary
Rifampicin shows promise for prosthetic device infections due to its tissue penetration and anti-biofilm activity. However, bacterial resistance necessitates cautious use and understanding of its action and potential pitfalls.
Area of Science:
- Microbiology
- Pharmacology
- Infectious Diseases
Context:
- Rifampicin, initially for tuberculosis, is now explored for prosthetic device infections.
- Prosthetic device infections are challenging due to bacterial biofilms.
- Rifampicin exhibits good tissue penetration and anti-biofilm efficacy.
Purpose:
- To review the mode of action of rifampicin against bacteria in biofilms.
- To discuss the potential benefits and limitations of using rifampicin for prosthetic device infections.
- To highlight the critical issue of emerging bacterial resistance to rifampicin.
Summary:
- Rifampicin possesses excellent tissue penetration and unique activity against bacteria within biofilms on prosthetic devices.
- The primary concern with rifampicin use is the rapid emergence of bacterial resistance.
- Understanding rifampicin's mechanism and potential pitfalls is crucial for effective clinical application.
Impact:
- Provides insights into optimizing rifampicin therapy for device-related infections.
- Emphasizes the need for strategies to mitigate rifampicin resistance.
- Informs clinical decision-making regarding the use of rifampicin in challenging infections.
More Related Videos
07:28Metabolic Profiling to Determine Bactericidal or Bacteriostatic Effects of New Natural Products using Isothermal Microcalorimetry
Published on: October 29, 2020
9.9K
09:57Visualization of the Charcoal Agar Resazurin Assay for Semi-quantitative, Medium-throughput Enumeration of Mycobacteria
Published on: December 14, 2016
12.0K
Related Concept Videos
01:23Pharmacokinetic–Pharmacodynamic Relationship: Influence of Elimination Half-Life on Effect Duration
141
Drug elimination from the body primarily occurs through metabolic and excretion pathways. Hepatic metabolism transforms lipophilic drugs into hydrophilic forms for excretion, typically via enzymatic processes classified as phase I (modification) and phase II (conjugation). Renal excretion eliminates drugs and metabolites through filtration and secretion in the kidneys. Impairment in liver or kidney function can hinder these processes, delaying drug clearance and extending the drug’s...
141
01:28Pulmonary Tuberculosis V
1.0K
Medical management of tuberculosis (TB) patients involves a comprehensive approach that includes diagnosis, treatment, and monitoring. The specific strategies can vary depending on the type of tuberculosis (latent or active), the patient's overall health status, and other considerations.
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the...
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the...
1.0K
01:28Inhibitors of Bacterial DNA Synthesis
130
Bacterial pathogens depend on precise and efficient DNA replication to sustain infection. Two type II topoisomerases—DNA gyrase and topoisomerase IV—are critical to this process, as they resolve DNA supercoiling and unlink chromosomes during replication. Fluoroquinolones, synthetic derivatives of quinolones, exploit this mechanism by stabilizing the transient DNA–enzyme cleavage complex, preventing strand religation, and causing lethal double-strand breaks. These...
130
01:24Drug Accumulation During Multiple Dosing: Intermittent IV Infusions
423
Intermittent intravenous (IV) infusion is a method of drug administration where medications are delivered over short infusion periods followed by intervals of no drug delivery. This approach helps to prevent sustained high drug concentrations in the bloodstream, reducing the risk of adverse effects associated with prolonged exposure. Unlike continuous infusion, steady-state concentrations may not be achieved during a single dosing cycle but can be reached through repeated...
423
01:28Pulmonary Tuberculosis II
2.5K
Tuberculosis, or TB, is a bacterial infectious disease caused by Mycobacterium tuberculosis. While its primary impact is on the lungs, leading to pulmonary tuberculosis, it can also affect various other organs, a condition referred to as extrapulmonary tuberculosis.
Here is a detailed explanation of its pathophysiology:
Transmission: The process begins when a person inhales droplet nuclei containing M. tuberculosis. These are typically released into the air when an individual with pulmonary or...
Here is a detailed explanation of its pathophysiology:
Transmission: The process begins when a person inhales droplet nuclei containing M. tuberculosis. These are typically released into the air when an individual with pulmonary or...
2.5K
01:25Inhibitors of Bacterial Protein Synthesis
106
Aminoglycosides constitute a highly potent class of bactericidal antibiotics that exert their antimicrobial effects by targeting the bacterial ribosome, specifically disrupting protein synthesis. These polycationic molecules consist of amino-modified sugars linked via glycosidic bonds to an aminocyclitol core such as 2-deoxystreptamine or streptamine. Their strong positive charges facilitate tight binding to the negatively charged phosphate backbone of ribosomal RNA (rRNA), primarily at the 16S...
106